On May 1, 2020, Éric Gosselin, BScAgr’91, FAB member since 2017 and partner in the Business Law Group in Montreal for McCarthy Tetrault LLP, stepped into the role of FAB Chair for a three-year term. He took some time to answer a few questions about himself, his role as Chair and his vision for the future of the FAB.
Read more in the June edition of the Macdonald E-Newsletter...
Chaque fois qu'Alain Bellemare prend la route de Louiseville, il laisse derrière lui son titre de président et chef de la direction de Bombardier pour mieux redevenir le fils, le frère, le neveu et le cousin.
Ici, l'homme de 55 ans renoue avec ses racines... et se dit toujours prêt pour une partie de cartes. Le 500.
Lire l'article complet: La Presse, le 13 janvier 2017
On Tuesday, Nov. 29, Footwear News will host its 2016 Achievement Awards in New York, honoring the best and brightest in the industry, including Aldo Bensadoun, the winner of the Manolo Blahnik Lifetime Achievement Award. Read on to learn more Mr. B’s accomplishments.
Read full article: Footwear News, November 29, 2016
Samira Sakhia, president of Knight Therapeutics, has joined Crescita Therapeutics Inc.’s board of directors. Prior to her current role, she was the chief financial officer of Paladin Labs. She holds a Bachelor of Commerce degree in Finance and Accounting and a Masters of Business Administration in Strategy and Marketing from McGill University and is a Chartered Professional Accountant. Additionally, Dr. Henrich Guntermann and Klaus von Lindeiner have tendered their resignations as board members of the company.
Crescita Therapeutics Inc. (Crescita or the Company), a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, today announced that Samira Sakhia, President of Knight Therapeutics, has joined its board of directors. Prior to her current role, Ms. Sakhia was the Chief Financial Officer of Paladin Labs. Ms.
A monthly roundup of ‘people on the move’ in Canada’s life science and biotech sectors.
...Samira Sakhia, former CFO of Paladin Labs Inc. , has joined the Knight Therapeutics Inc. team as president and as member of the company’s board of directors. Ms. Sakhia served as the CFO at Paladin (acquired by Endo International plc February 2014), from 2001 to 2015. She holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant.
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today announced that Samira Sakhia, former CFO of Paladin Labs Inc. ("Paladin"), will be joining the Knight team as President and member of the Board of Directors. In her new role, beginning on August 31, 2016, Samira will report to Jonathan Ross Goodman, CEO of Knight.
La Presse donne la parole aux grands dirigeants du Québec. Chaque vendredi, un patron répond à cinq questions posées par le chef d'entreprise interviewé la semaine précédente. Et ainsi de suite.
LE PARCOURS D'ALAIN BELLEMARE EN BREF
Âge : 55 ans
Études : Alain Bellemare est titulaire d'un baccalauréat en génie mécanique de l'Université de Sherbrooke et d'un MBA de l'Université McGill.
En poste depuis : février 2015
Nombre d'employés : 65 000, dont 17 000 au Québec
A Montreal man who recently treated a young Newfoundland soccer team to a surprise NHL game, including a private audience with Montreal Canadiens' star P.K. Subban, says giving back is a big part of his personal philosophy.
Alain Bellemare, 54, took the helm of Bombardier Inc. in February. The company’s US$5.4-billion CSeries passenger jet, the largest plane built by the company, was certified on Friday by Transport Canada.
Paul Tellier se dit très déçu que la direction de Bombardier (T.BBD.B) n'ait pas agi plus rapidement pour corriger le tir et remplacer son PDG. Et il croit qu'aujourd'hui, Alain Bellemare doit disposer de toute la latitude voulue pour manoeuvrer.
Read full article: LaPresse, November 4, 2015
Nuvo Research Inc. (TSX:NRI) (Nuvo or the Company), a specialty pharmaceutical company with growing revenues and a diverse portfolio of topical and immunology products, today announced the appointment of Samira Sakhia to its Board of Directors.
Read full article: Dallas South News, November 3, 2015
Bombardier says it has no plans to pull the plug on the CSeries even though its efforts to secure a rescue deal from Airbus stoked fears about the future of the aircraft program and the company itself.
… Karl Moore, professor at McGill University’s Desautels Faculty of Management, said Bombardier may sell a majority stake in its transportation division to raise funds but he’d be “astonished” if Bombardier’s new CEO Alain Bellemare bailed on the CSeries that is two years late and $2 billion over budget.
Reports that Bombardier Inc. approached rival Airbus Group to sell a majority stake of the CSeries aircraft program have set off fears that the company is in deeper trouble.
... “They are in trouble, and there are real cash flow issues,” said McGill University business professor Karl Moore, noting that’s why Bellemare was brought in as CEO. “It’s not a trivial thing to do.”
